Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: March 22, 2023

GLIMEPIRIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

When do Glimepiride patents expire, and when can generic versions of Glimepiride launch?

Glimepiride is a drug marketed by Accord Hlthcare, Actavis Labs Fl Inc, Aurobindo Pharma Ltd, Carlsbad, Chartwell Molecular, Dr Reddys Labs Ltd, Epic Pharma Llc, Hikma Pharms, Indoco Remedies, Micro Labs, Mylan, Prinston Inc, Ranbaxy, Ranbaxy Labs Ltd, Teva, and Watson Labs. and is included in seventeen NDAs.

The generic ingredient in GLIMEPIRIDE is glimepiride. There are sixteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the glimepiride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Glimepiride

A generic version of GLIMEPIRIDE was approved as glimepiride by CHARTWELL MOLECULAR on October 6th, 2005.

  Try a Trial

Drug patent expirations by year for GLIMEPIRIDE
Drug Prices for GLIMEPIRIDE

See drug prices for GLIMEPIRIDE

Drug Sales Revenue Trends for GLIMEPIRIDE

See drug sales revenues for GLIMEPIRIDE

Recent Clinical Trials for GLIMEPIRIDE

Identify potential brand extensions & 505(b)(2) entrants

Peking University First HospitalPhase 4
Jiangsu Province Geriatric InstitutePhase 4
Peking University People's HospitalPhase 4

See all GLIMEPIRIDE clinical trials

Pharmacology for GLIMEPIRIDE
Drug ClassSulfonylurea

US Patents and Regulatory Information for GLIMEPIRIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Prinston Inc GLIMEPIRIDE glimepiride TABLET;ORAL 077370-002 Dec 23, 2005 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Micro Labs GLIMEPIRIDE glimepiride TABLET;ORAL 091220-005 Jun 29, 2012 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ranbaxy Labs Ltd GLIMEPIRIDE glimepiride TABLET;ORAL 076875-004 Oct 6, 2005 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ranbaxy GLIMEPIRIDE glimepiride TABLET;ORAL 077366-002 Oct 6, 2005 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.